Plasma Protein Therapeutics Market Outlook 2027: Expanding from US$ 22.41 Billion to US$ 42.88 Billion with an 8.1% CAGR | Exclusive Report by TMR

The global plasma protein therapeutics market, valued at US$22.41 billion in 2018, is poised for significant growth over the forecast period. It is projected to expand at a compound annual growth rate (CAGR) of 7.0% from 2019 to 2027, reaching approximately US$42.88 billion by the end of 2027. This robust expansion reflects the increasing demand for plasma-derived therapies to treat a range of chronic and rare diseases, coupled with advancements in plasma collection and fractionation technologies. As healthcare systems prioritize life-saving treatments, the plasma protein therapeutics market is set to nearly double in value, reinforcing its critical role in global medicine through 2027.

Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10424

Understanding Plasma Protein Therapeutics
Plasma protein therapeutics are biologic drugs derived from human plasma, the liquid component of blood rich in proteins like immunoglobulins, albumin, and clotting factors. These therapies treat conditions such as immune deficiencies, hemophilia, and autoimmune disorders, offering targeted relief where synthetic alternatives fall short. The market's 2018 valuation of US$22.41 billion underscores its established importance, with the projected rise to US$42.88 billion by 2027 highlighting its growing necessity amid rising disease prevalence and therapeutic innovation.

The 7.0% CAGR signals a dynamic growth phase, driven by both medical need and technological progress. Plasma-derived products remain a lifeline for patients with rare and chronic conditions, ensuring sustained market momentum.

Key Drivers of Market Growth

Several factors are propelling the plasma protein therapeutics market toward its US$42.88 billion valuation by 2027. First, the rising incidence of rare and chronic diseases is a primary driver. Conditions like primary immunodeficiency disorders (PIDD), affecting millions globally, and hemophilia, a genetic bleeding disorder, rely heavily on immunoglobulin and clotting factor therapies. An aging population and improved diagnostics further increase the patient pool, boosting demand.

Second, advancements in plasma collection and processing are fueling growth. Improved fractionation techniques enhance yield and purity, while expanded donor networks-supported by organizations like the Plasma Protein Therapeutics Association-ensure a steady supply of raw plasma. Innovations like recombinant alternatives complement traditional plasma-derived products, aligning with the market's 7.0% CAGR.

Third, growing awareness and healthcare investments are enhancing access. Governments and insurers in developed regions are prioritizing coverage for high-cost therapies, while patient advocacy groups raise awareness about conditions treatable with plasma proteins. This dual push supports the market's expansion, particularly for high-demand products like intravenous immunoglobulin (IVIG).

Leading Players:

Baxter International
Biotests
CSL Behring
GRIFOLS, S.A
Kedrion
Octapharma USA, Inc.
Shire Plc.
China Biologics.

Visit our report to discover essential insights and analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10424

Market Segmentation and Regional Insights

The market segments by product type, application, and geography. Immunoglobulins lead, driven by their use in immune deficiencies and autoimmune diseases, followed by albumin (for burns and shock) and coagulation factors (for bleeding disorders). By application, immunology and hematology dominate, with emerging use in critical care. Distribution occurs via hospitals, specialty clinics, and pharmacies, with hospitals holding the largest share.

Regionally, North America accounted for a significant portion of the US$22.41 billion valuation in 2018, driven by high demand, advanced infrastructure, and a strong plasma collection network in the United States. Europe followed, with robust markets in Germany and France, supported by universal healthcare systems. The Asia-Pacific region, however, was poised for the fastest growth through 2027, fueled by rising healthcare spending, increasing disease awareness, and expanding plasma fractionation capabilities in China and India.

Challenges and Opportunities

The market faced challenges during this period. High production costs and complex manufacturing processes-requiring stringent safety and quality controls-limited scalability. Plasma supply shortages, reliant on voluntary donations, occasionally disrupted availability, while regulatory hurdles delayed new product approvals. Competition from recombinant therapies also pressured traditional plasma-derived options.

These challenges, however, opened opportunities. Companies investing in automated fractionation or synthetic biology could improve efficiency and reduce costs, supporting the push to US$42.88 billion. Expanding donor incentives and plasma collection centers in emerging markets addressed supply gaps, while novel indications for plasma proteins-like neurological disorders-offered growth potential beyond projections.

The Road to 2027

By 2027, the global plasma protein therapeutics market reached its projected US$42.88 billion, reflecting nine years of strong growth at a 7.0% CAGR from US$22.41 billion in 2018. This achievement was driven by disease prevalence, technological advancements, and global outreach. As the forecast period concluded, the market's trajectory suggested continued expansion, with potential for further gains as new therapies and markets emerged.

In conclusion, the plasma protein therapeutics market demonstrated remarkable growth from 2018 to 2027. Rising from US$22.41 billion to US$42.88 billion, it addressed critical health needs with life-saving impact. Stakeholders-from plasma collectors to biopharma firms-played a pivotal role in this success, ensuring that these therapies remained a vital resource for patients worldwide through 2027 and beyond.

Explore Latest Research Reports by Transparency Market Research:

Pharma 4.0 Market: https://www.pharmiweb.com/press-release/2025-03-18/pharma-40-market-size-will-estimated-to-grow-at-a-cagr-of-177-by-2035-driven-by-digital-transformation-in-drug-manufacturing-exclusive-report-by

Dialysis Equipment Market: https://www.pharmiweb.com/press-release/2025-03-18/dialysis-equipment-market-poised-to-surpass-us-252-bn-by-2035-amidst-rising-ckd-cases-and-technological-advancements-tmr-insights

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.